Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes
dc.contributor.author | El Ghali, Amer | |
dc.contributor.author | Morrisette, Taylor | |
dc.contributor.author | Alosaimy, Sara | |
dc.contributor.author | Lucas, Kristen | |
dc.contributor.author | Tupayachi-Ortiz, Maria G. | |
dc.contributor.author | Vemula, Raaga | |
dc.contributor.author | Wadle, Carly | |
dc.contributor.author | Philley, Julie V. | |
dc.contributor.author | Mejia-Chew, Carlos | |
dc.contributor.author | Hamad, Yasir | |
dc.contributor.author | Stevens, Ryan W. | |
dc.contributor.author | Zeuli, John D. | |
dc.contributor.author | Webb, Andrew J. | |
dc.contributor.author | Fiske, Christina T. | |
dc.contributor.author | Simonyan, Anahit | |
dc.contributor.author | Cimino, Christo L. | |
dc.contributor.author | Mammadova, Mehriban | |
dc.contributor.author | Umana, Virginia E. | |
dc.contributor.author | Hasbun, Rodrigo | |
dc.contributor.author | Butt, Saira | |
dc.contributor.author | Molina, Kyle C. | |
dc.contributor.author | Thomas, Michael | |
dc.contributor.author | Kaip, Emily A. | |
dc.contributor.author | Bouchard, Jeannette | |
dc.contributor.author | Gore, Tristan W. | |
dc.contributor.author | Howard, Catessa | |
dc.contributor.author | Cabanilla, M. Gabriela | |
dc.contributor.author | Holger, Dana J. | |
dc.contributor.author | Frens, Jeremy J. | |
dc.contributor.author | Barger, Melissa | |
dc.contributor.author | Ong, Aaron | |
dc.contributor.author | Cohen, Keira A. | |
dc.contributor.author | Rybak, Michael J. | |
dc.contributor.department | Medicine, School of Medicine | |
dc.date.accessioned | 2024-03-28T09:27:21Z | |
dc.date.available | 2024-03-28T09:27:21Z | |
dc.date.issued | 2023 | |
dc.description.abstract | Infections due to nontuberculous mycobacteria (NTM) continue to increase in prevalence, leading to problematic clinical outcomes. Omadacycline (OMC) is an aminomethylcycline antibiotic with FDA orphan drug and fast-track designations for pulmonary NTM infections, including Mycobacteroides abscessus (MAB). This multicenter retrospective study across 16 U.S. medical institutions from January 2020 to March 2023 examined the long-term clinical success, safety, and tolerability of OMC for NTM infections. The cohort included patients aged ≥18 yr, who were clinically evaluable, and` had been treated with OMC for ≥3 mo without a previous diagnosis of cystic fibrosis. The primary outcome was 3 mo clinical success, with secondary outcomes including clinical improvement and mortality at 6- and 12 mo, persistence or reemergence of infection, adverse effects, and reasons for OMC utilization. Seventy-five patients were included in this analysis. Most patients were female (48/75, 64.0%) or Caucasian (58/75, 77.3%), with a median (IQR) age of 59 yr (49–67). Most had NTM pulmonary disease (33/75, 44.0%), skin and soft tissue disease (19/75, 25.3%), or osteomyelitis (10/75, 13.3%), and Mycobacterium abscessus (60/75, 80%) was the most commonly isolated NTM pathogen. The median (IQR) treatment duration was 6 mo (4 – 14), and the most commonly co-administered antibiotic was azithromycin (33/70, 47.1%). Three-month clinical success was observed in 80.0% (60/75) of patients, and AEs attributable to OMC occurred in 32.0% (24/75) of patients, leading to drug discontinuation in 9.3% (7/75). | |
dc.eprint.version | Final published version | |
dc.identifier.citation | El Ghali A, Morrisette T, Alosaimy S, et al. Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes. Antimicrob Agents Chemother. 2023;67(10):e0082423. doi:10.1128/aac.00824-23 | |
dc.identifier.uri | https://hdl.handle.net/1805/39564 | |
dc.language.iso | en_US | |
dc.publisher | American Society for Microbiology | |
dc.relation.isversionof | 10.1128/aac.00824-23 | |
dc.relation.journal | Antimicrobial Agents and Chemotherapy | |
dc.rights | Attribution 4.0 International | en |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.source | PMC | |
dc.subject | Omadacycline | |
dc.subject | Nontuberculous mycobacteria | |
dc.subject | Mycobacterium abscessus | |
dc.subject | Culture conversion | |
dc.title | Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes | |
dc.type | Article |